홈 > 시장보고서 > 의약품 > 암

시장보고서

상품코드

1297826

세계의 급성 림프구성 백혈병 치료제 시장(2023-2030년)

Global Acute Lymphocytic Leukemia Therapeutics Market - 2023-2030

발행일: 2023년 06월 | 리서치사:

DataM Intelligence | 페이지 정보: 영문 195 Pages | 배송안내 : 1-2일 (영업일 기준)

■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

시장 개요

급성 림프구성 백혈병 치료제 세계 시장 규모는 2022년 29억 달러, 2030년에는 45억 달러에 달할 것으로 예상되며, 2023-2030년의 예측 기간 동안 5.8%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 소아 백혈병 증가와 신약 임상시험 증가는 급성 림프구성 백혈병 치료제 시장 동향에 대한 수요를 증가시키고 있습니다.

B 또는 T림프모세포 악성 종양은 급성 림프구성 백혈병(ALL)으로 알려져 있으며, 미성숙하고 비정상적인 림프구와 그 전구세포의 억제되지 않은 증식을 특징으로 합니다. 이 과정은 결국 골수 성분과 다른 림프계 장기의 대체를 유발하여 특징적인 병형을 형성합니다.

급성 림프구성 백혈병 치료제 시장 범위는 표적치료제 및 면역치료, 방사선치료, 화학요법, 줄기세포 이식 등의 치료법으로 구성되어 있으며, 급성 림프구성 백혈병 치료제 시장 점유율을 확대하고 있습니다. 급성 림프구성 백혈병 치료제 세계 시장은 연구 개발 증가를 포함한 요인의 결과로 확대되고 있으며, 각국의 향후 의료 승인도 급성 림프구성 백혈병 치료제 시장 성장에 대한 밝은 전망을 낳고 있습니다.

시장 역학

급성림프성백혈병 발생률 증가로 급성림프성백혈병 치료제 시장 성장 견인

급성 림프구성 백혈병 시장 확대의 주요 요인은 급성 림프구성 백혈병(ALL)의 발병률 증가입니다. 매년 남녀 10만 명당 약 1.7명의 신규 환자가 보고되고 있습니다. 미국암협회의 예측에 따르면, 2023년 국내에서는 약 6,540명의 급성 림프구성 백혈병(ALL)이 새로 발병할 것으로 예상되며, 그 중 남성 3,660명, 여성 2,880명, ALL 관련 사망자는 약 1,390명(남성 700명, 여성 690명)이 될 것으로 예상하고 있습니다.

ALL에 걸릴 확률이 가장 높은 연령대는 5세 이하의 어린이입니다. 그 후 20 대 중반까지 위험이 점차 감소하고 50 세 전후에 다시 서서히 증가하기 시작합니다. 따라서 림프성 백혈병 사례 증가는 급성 림프구성 백혈병 치료제 시장을 주도하고 있습니다.

연구개발 활성화는 제조업체에 유리한 기회를 가져다줍니다.

연구자들은 미래에 대한 통찰력을 제공하고 치료에 대한 더 나은 접근 방식을 제공하는 다양한 개발을 진행하고 있습니다. 예를 들어, 연구진은 자가 복제하는 백혈병 시작 세포의 특성을 더 자세히 파악하여 고위험군 B-ALL이 어떻게 재발하는지를 더 잘 이해하고자 했습니다. 이 세포가 어떤 유전자에 의해 활성화되는지 알아보기 위해 연구팀은 이식 연구와 함께 단일 세포 RNA 시퀀싱을 사용하여 세포의 증식을 조사했습니다.

백혈병은 백혈병 시작 세포가 휴면상태에 있을 때 해당과 저산소증 신호전달을 억제함으로써 백혈병이 조절되는 것으로 알려져 있습니다. 산화적 인산화 상태로 몰아넣는 과정에서 세포는 백혈병을 유발할 수 있는 능력을 잃게 됩니다. 따라서 이러한 요인들은 급성 림프구성 백혈병 치료제 시장 규모의 성장 기회를 창출할 것으로 보입니다.

치료에 따른 합병증으로 시장 성장 저해

지지 요법이 개선되었지만 치료 독성으로 인한 사망을 예방하는 것은 여전히 어렵다. 종양 붕괴 증후군은 화학요법으로 인해 암세포가 용해되어 칼륨, 요산, 칼슘, 인과 같은 특정 내부 요소가 방출되어 발생하므로 주의해야 합니다. 이러한 물질은 고농도로 존재하면 독성을 나타내며 종종 신부전을 유발할 수 있습니다.

종양 붕괴 증후군은 수액이나 스테로이드 전처치 등으로 피할 수 있는 경우가 많습니다. 그러나 이런 경우의 치료법은 집중적인 수액 요법입니다. 급성 림프구성 백혈병은 치료 후에도 재발할 수 있습니다. 재발은 21년 후까지 발생할 수 있습니다. 어린이와 부모, 가족에게 심리적 지지를 제공하는 등 어린 자녀의 암 치료와 관련된 추가적인 문제를 해결하는 것이 매우 중요합니다.

COVID-19의 영향 분석

코로나19 팬데믹과 세계 각국의 봉쇄 조치로 인해 모든 산업 분야의 기업 재무 건전성이 영향을 받고 있습니다. 이에 미국 식품의약국(FDA)은 코로나19 공중보건 비상사태 기간 동안 임상시험 참여자의 안전을 보장하고 임상시험의 무결성 위험을 최소화하기 위한 일반적인 고려사항을 포함한 가이드라인을 발표하여 임상시험 의뢰자와 연구자를 지원하고 임상시험의 안전과 우수 임상시험 관리기준(GCP)을 준수할 수 있도록 했습니다. 가이드라인을 발표했습니다.

러시아-우크라이나 분쟁의 영향 분석

러시아-우크라이나 분쟁은 이 지역의 주요 시장 기업 수가 적기 때문에 세계 급성 림프구성 백혈병 치료제 시장에 미치는 영향은 미미할 것으로 추정됩니다. 그러나 원자재 수입 및 수출의 영향은 예측 기간 동안 세계 급성 림프구성 백혈병 치료제 시장의 성장에 거의 영향을 미치지 않을 것으로 예상됩니다.

Market Overview

The Global Acute Lymphocytic Leukemia Therapeutics Market size reached US$ 2.9 billion in 2022 and is expected to reach US$ 4.5 billion by 2030 and is expected to grow with a CAGR of 5.8% during the forecast period 2023-2030. Increasing leukemia in children and the growing clinical trials for novel drugs are driving up demand for acute lymphocytic leukemia therapeutics market trends.

B or T lymphoblasts malignancy is known as Acute lymphocytic leukemia (ALL) that is characterized by unchecked proliferation of immature, abnormal lymphocytes and their progenitors. This process eventually results in the replacement of bone marrow components and other lymphoid organs, producing a distinctive disease pattern.

The acute lymphocytic leukemia therapeutics market scope comprises therapy as Targeted Drugs & Immunotherapy, Radiation Therapy, Chemotherapy and Stem Cell Transplantation, which has increased the acute lymphocytic leukemia therapeutics market share. The global market for acute lymphocytic leukemia therapeutics is expanding as a result of factors including increasing research and development and their upcoming medical approvals across countries are also creating a positive outlook for the acute lymphocytic leukemia therapeutics market growth.

Market Dynamics

An Increase in the Incidence of Acute Lymphocytic Leukemia Drives the Growth of the Acute Lymphocytic Leukemia Therapeutics Market

The primary driver of this market's expansion globally is the increasing incidence of acute lymphocytic leukemia (ALL). Approximately 1.7 new cases per 100,000 men and women are reported annually. According to projections from the American Cancer Society, there will be approximately 6,540 new instances of acute lymphocytic leukemia (ALL) in the country in 2023 (including kids and adults), comprising 3,660 male cases and 2,880 female cases and approximately 1,390 ALL-related deaths, including 700 male cases and 690 female cases.

Children under the age of 5 have the highest chance of developing ALL. The risk then gradually decreases until the mid-20s and then slowly starts to increase again around age 50. Hence, the growing cases of lymphocytic leukemia are driving the acute lymphocytic leukemia therapeutics market.

Rising Research and Development Creates Lucrative Opportunities for Manufacturers

Various developments are being done by the researchers that will provide future insight and will provide a better approach to treatment. For instance, researchers hoped to learn more about the characteristics of self-renewing leukemia-initiating cells to better understand how they cause high-risk B-ALL to relapse. To determine which genes these cells were activating at different times, they utilized single-cell RNA sequencing in conjunction with transplant studies to examine the cells' growth.

The leukemia was found to be controlled by suppressing glycolysis and hypoxia signaling in leukemia-initiating cells when they were dormant. In the process of being driven back to the oxidative phosphorylation nation, the cells lost their ability to cause leukemia. Thus these factors will create an opportunity for the growth of the acute lymphocytic leukemia therapeutics market size.

Complications Associated With the Treatment Will Hamper the Growth of the Market

Although supportive care has improved, it is still difficult to prevent death brought on by treatment toxicity. Tumor Lysis Syndrome, which happens when chemotherapy induces cancer cells to lyse and release certain internal elements like potassium, uric acid, calcium and phosphorus, should be kept an eye out for. These substances produce toxicity when present in high concentrations, which frequently results in renal failure.

Tumor Lysis Syndrome is often avoided by pretreatment with fluids and steroids. But if it does, the remedy is intensive fluid therapy. Acute lymphocytic leukemia might return even after treatment. Relapses might happen up to 21 years past. It is crucial to address additional concerns related to a young kid's cancer treatment, such as giving the kid, their parents and their family psychological support.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global acute lymphocytic leukemia therapeutics market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global acute lymphocytic leukemia therapeutics market growth over the forecast period.

Segment Analysis

The global acute lymphocytic leukemia therapeutics market is segmented based on treatment type, therapy, cell type, distribution channel and region.

Philadelphia Chromosome From Cell Type Segment Accounts for 40.3% of Market Share Owing to Rising Novel Product Launches

Acute lymphoblastic leukemia (ALL), which has the Philadelphia chromosome (Ph+ ), makes up around one-fourth of adult ALL cases. It often has an aggressive clinical course, does not react well to conventional chemotherapy and is highly plausible. Ph+ ALL is a rapidly developing condition for which there are presently no front-line targeted therapies authorized in the United States.

A potent therapy that can prevent the emergence of challenging-to-treat mutations, which are linked to suboptimal long-term results, is urgently required. Since the invention of tyrosine kinase inhibitors (TKIs), the landscape of Ph+ ALL therapy has improved. The PhALLCON study compares ICLUSIG and imatinib in combination with low-intensity chemotherapy as a primary therapy for adult patients having newly diagnosed Ph+ ALL. It is a Phase 3 randomized, multinational, open-label multicenter experiment.

Geographical Analysis

North America Accounted For Approximately 41.3% Of the Market Share Owing to The Strong Presence Of Major Players and Increasing Technological Advancements

Manufacturers have chances to expand their operations in this region because of the rising demand for acute lymphocytic leukemia therapeutics for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised the industrial production of acute lymphocytic leukemia therapeutics, which has increased the demand.

Rising new drugs for different types of lymphocytic leukemia will drive the market growth. Growth is also fueled by rising technological advancements, regulatory approvals and novel product launches. Researchers are becoming more aware of various kinds of treatment approaches for acute lymphocytic leukemia, leading to the expansion of the market in this region. These factors show the dominance of North America.

Competitive Landscape

The major global players in the acute lymphocytic leukemia therapeutics market include: Merck & Co. Inc., Pfizer Inc., Bristol-Myers Squibb, Novartis AG, Takeda Pharmaceutical Company Limited, Sanofi, Spectrum Pharmaceuticals, Inc., Rare Disease Therapeutics, Inc., SymBio Pharmaceuticals Limited and Erytech Pharma among others.

Why Purchase the Report?

To visualize the global acute lymphocytic leukemia therapeutics market segmentation based on treatment type, therapy, cell type, distribution channel and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of acute lymphocytic leukemia therapeutics market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The Global Acute Lymphocytic Leukemia Therapeutics Market Report Would Provide Approximately 53 Tables, 54 Figures and 195 Pages.

Target Audience 2023

Manufacturers / Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Treatment Type
3.2. Snippet by Therapy
3.3. Snippet by Cell Type
3.4. Snippet by End User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Initiatives Taken by the Government and Private Organizations
  - 4.1.1.2. The Growing Incidence of Acute Lymphocytic Leukemia
- 4.1.2. Restraints
  - 4.1.2.1. Complications Associated with the Treatment
- 4.1.3. Opportunity
  - 4.1.3.1. Rising Research and Development
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. By Treatment Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 7.1.2. Market Attractiveness Index, By Treatment Type
7.2. Drugs
- 7.2.1. Pegasparaginase (Oncaspar) *
  - 7.2.1.1. Introduction
  - 7.2.1.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.2. Cyclophosphamide (Neosar)
- 7.2.3. Daunorubicin (Cerubidine)
- 7.2.4. Doxorubicin (Adriamycin)
- 7.2.5. Nelarabine (Arranon)
- 7.2.6. Rituximab (Rituxan)
- 7.2.7. Nilotinib (Tasigna)
- 7.2.8. Others
7.3. Surgery
7.4. Others

8. By Therapy

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 8.1.2. Market Attractiveness Index, By Therapy
8.2. Targeted Drugs & Immunotherapy *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Radiation Therapy
8.4. Chemotherapy
8.5. Stem Cell Transplantation

9. By Cell Type

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
- 9.1.2. Market Attractiveness Index, By Cell Type
9.2. Philadelphia Chromosome *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Precursor B-Cell ALL
9.4. T-Cell ALL

10. By End user

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 10.1.2. Market Attractiveness Index, By End User
10.2. Hospital & Hospital Pharmacy *
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Radiation Therapy and Online Pharmacy
10.4. Ambulatory Surgical Centers
10.5. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.7.1. The U.S.
  - 11.2.7.2. Canada
  - 11.2.7.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.7.1. Germany
  - 11.3.7.2. The U.K.
  - 11.3.7.3. France
  - 11.3.7.4. Italy
  - 11.3.7.5. Spain
  - 11.3.7.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.7.1. Brazil
  - 11.4.7.2. Argentina
  - 11.4.7.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.7.1. China
  - 11.5.7.2. India
  - 11.5.7.3. Japan

Australia

11.5.7.4. Rest of Asia-Pacific

11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. Amgen Inc. *
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Bristol-Myers Squibb
13.3. Pfizer Inc.
13.4. Novartis AG
13.5. Sanofi
13.6. Takeda Pharmaceutical Company Limited
13.7. Spectrum Pharmaceuticals, Inc.
13.8. SymBio Pharmaceuticals Limited
13.9. Rare Disease Therapeutics, Inc.
13.10. Erytech Pharma

LIST NOT EXHAUSTIVE

14. Appendix

14.1. About Us and Services
14.2. Contact Us

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF & Excel (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,350

￦ 6,294,000

PDF & Excel (Multiple User License)

PDF 보고서를 동일 사업장에서 7명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,850

￦ 7,017,000

PDF & Excel (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,850

￦ 11,358,000

※ 부가세 별도